Visit this section

Healthcare professionals

Public
wooden-background

EPA 2020 – 28th European Congress of Psychiatry

4 – 7 July 2020

wooden-background

EPA 2020 – 28th European Congress of Psychiatry

4 – 7 July 2020

Follow our congress highlights by subscribing to our newsletter

SYMPOSIUM: THE DIFFERENT ASPECTS OF SCHIZOPHRENIA TREATMENT

SYMPOSIUM: THE DIFFERENT ASPECTS OF SCHIZOPHRENIA TREATMENT

Summary of presentations on schizophrenia treatment and role of cariprazine during a satellite symposium held during the 28th European Congress of Psychiatry.

SYMPOSIUM: THE DIFFERENT ASPECTS OF SCHIZOPHRENIA TREATMENT

SYMPOSIUM: THE DIFFERENT ASPECTS OF SCHIZOPHRENIA TREATMENT

Summary of presentations on schizophrenia treatment and role of our product during a satellite symposium held during the 28th European Congress of Psychiatry.

COD: 300020/R30

ANTIPSYCHOTIC MONOTHERAPY OR POLYPHARMACY: WHAT’S THE  EVIDENCE?

ANTIPSYCHOTIC MONOTHERAPY OR POLYPHARMACY: WHAT’S THE EVIDENCE?

There is emerging observational evidence that some combinations of antipsychotics might be beneficial but monotherapy remains the standard of practice.

BEST OF 2019: ARTICLE OVERVIEW OF RESEARCH IN SCHIZOPHRENIA

BEST OF 2019: ARTICLE OVERVIEW OF RESEARCH IN SCHIZOPHRENIA

During an educational symposium at the EPA 2020 Congress, Prof. Pierre-Michel Llorca highlighted some of the notable research articles published in 2019.

GREATER EFFORTS NEEDED TO INTEGRATE CARE FOR PEOPLE WITH SCHIZOPHRENIA

GREATER EFFORTS NEEDED TO INTEGRATE CARE FOR PEOPLE WITH SCHIZOPHRENIA

There is a need to increase the use of integrated care for schizophrenia to improve the real-life functional outcomes of people with the illness.

BOOK REVIEW: MANAGING NEGATIVE SYMPTOMS OF SCHIZOPHRENIA

BOOK REVIEW: MANAGING NEGATIVE SYMPTOMS OF SCHIZOPHRENIA

Managing negative symptoms of schizophrenia is the subject of a new book published by Oxford University Press and highlighted at the virtual 28th EPA Congress.

COD: 300020/R33

TREATING SCHIZOPHRENIA WITH OUR PRODUCT

Who are the patients that can benefit from therapy with our product in real-life practice? This was a topic addressed by Professor Andrea Fagiolini, University of Siena, Italy
COD: 300020/R36. Submitted to AIFA XX/XX/2020

TREATING SCHIZOPHRENIA WITH CARIPRAZINE

Who are the patients that can benefit from therapy with cariprazine in real-life practice? This was a topic addressed by Professor Andrea Fagiolini, University of Siena, Italy
COD: 300020/R36. Submitted to AIFA XX/XX/2020

ADDRESSING FUNCTIONING IN SCHIZOPHRENIA

Schizophrenia treatment today is much more focused on overall recovery than just response or remission. The goal is to help people function as normally as possible in real life, said Prof. Peter Falkai, Ludwig-Maximilian University Munich, Germany

OUR PRODUCT IN ACUTE SCHIZOPHRENIA

Real-world clinical experience with Our product in the Treatment of Acute Schizophrenia, shared by Dr Jose Manuel Montes, University Hospital Ramón y Cajal, Madrid, Spain
COD: 300020/R37. Submitted to AIFA XX/XX/2020

CARIPRAZINE IN ACUTE SCHIZOPHRENIA

Real-world clinical experience with Cariprazine in the Treatment of Acute Schizophrenia, shared by Dr Jose Manuel Montes, University Hospital Ramón y Cajal, Madrid, Spain
COD: 300020/R37. Submitted to AIFA XX/XX/2020

METACOGNITION KEY TO IMPROVING FUNCTIONING IN SCHIZOPHRENIA?

METACOGNITION KEY TO IMPROVING FUNCTIONING IN SCHIZOPHRENIA?

Professor Dame Til Wykes discussed new developments in cognitive remediation for schizophrenia at the virtual 28th European Congress of Psychiatry.

Showing 0 result(s).
Please log in to see 0 more result(s).